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Continuous Glucose Monitoring and Diabetes Management During Pregnancy 
Abstract 
According to the Scope of Practice, Standards of Practice, and the Standards of 
Professional Performance for Diabetes Educators, registered nurses play an integral role in the 
promotion of diabetes self-management education and training in diabetes care (AADE, 2017). 
This paper upholds the standards set forth by the American Association of Diabetes Educators 
(2017) governing body, to stimulate the process of peer review, promote documentation of the 
outcomes of diabetes self-management education and training (DSME/T), encourage research to 
validate practice and improve quality DSME/T and diabetes care for pregnant women who use 
continuous glucose monitoring. To improve registered nurse education and diabetes practice, the 
Continuous Glucose Monitoring and Diabetes Management During Pregnancy Program was 
presented to the management and leadership of a high-risk subspecialty unit of a major Northern 
California healthcare maintenance organization. The implementation unit provided the staff, 
resources, and interest needed to support the project. The information provided in this paper 
discuss the needs assessment that was conducted as a basis for implementation of the pilot 
project. The SWOT analysis and Work Breakdown Structure (WBS) are project management 
tools that were utilized as part of the proposed Continuous Glucose Monitoring and Diabetes 
Management During Pregnancy Program Doctor of Nursing project. The SWOT analysis 
provides details about barriers to the project, support for the need, and objectives enacted to 
overcome obstacles, and elicited sponsor, provider, and team member support. The WBS was 
used as a communication tool to inform, update, and review progress to ensure the project was 





$3,000.00 to successfully implement the project. The outcome measurement tool used to 
determine the success of the project was qualitative data received from the registered nurses 
upon completion of the CGM device training modules. Qualitative data was gathered from the 
registered nurses using Qualtrics pre- and post-education and training. The secondary outcome 
measurement tools were the latest lab result HgbA1c of <7.0 mg/dl and a reduction of 







Diabetes and Pregnancy 
Safely achieving near-normal blood glucose levels remain the primary goal of clinicians 
who provide care for pregnant women with preexisting and gestational diabetes. However, the 
number of women affected by preexisting diabetes has increased over the years, making 
achieving near-normal blood glucose challenging due to many factors, including maternal 
obesity. Since 2010 the United States has experienced an increase in prevalence of obesity by 
17.8%; likewise, the upward trend of diabetes has seen a similar increase (Bhupathiaju & Hu, 
2016). According to researchers (Bhupathiaju & Hu, 2016; Hunt & Schuller, 2007), obesity is a 
major risk factor for type 2 diabetes, is considered a public health problem, and affects women 
more than men. Researchers (Hunt & Schuller, 2007) suggests the incidence of diabetes 
continues to rise, increasing the risk of diabetes during pregnancy of women in their child-
bearing years. The prevalence of gestational diabetes in a population reflects the prevalence of 
type 2 diabetes in that population (Hunt & Schuller, 2007), due in part to women with gestational 
diabetes being at a greater risk of converting to type 2 diabetes within five to 10 years of giving 
birth (Kim, et al., 2002). Further, as the overall rate of obesity and diabetes have risen over the 
years, so has the number of pregnant women with preexisting diabetes. From 2012-2016, the 
U.S. prevalence of preexisting diabetes during pregnancy rose from 0.7% to 0.9% (CDC, 2018). 
In 2009, roughly 1%-2% of pregnant women diagnosed with either preexisting diabetes or 
complicated gestational diabetes required antihyperglycemics to control blood glucose (CDC, 
2013, Law, et al., 2015, Sung, et al., 2012). These statistics are important to note because the 





women, requiring increasing doses of antihyperglycemics to control diabetes during pregnancy, 
while at the same time increasing their chances of episodic hypoglycemia. 
During the Consensus Conference of the American Association of Clinical 
Endocrinologists and American College of Endocrinology, leading experts in the field 
determined CGM is likely to provide benefits for women with diabetes who are planning 
pregnancy, as well as women with gestational diabetes (Fonseca, et. al., 2016). Further, 
consensus participants unanimously agreed that patients who are prescribed antihyperglycemics 
may also benefit, but barriers to the technology exist. CGM technology allows clinicians to 
recognize fluctuations in blood glucose values, but this requires education and training. 
For women with preexisting diabetes, blood glucose management in pregnancy begins at 
the first prenatal visit. For some women, gestational diabetes is diagnosed later in the pregnancy 
due to hormonal changes that occur within the placenta (Ngala, et al. 2017). Lifestyle 
management, medical nutrition therapy, physical activity, stress, and sleep hygiene should be 
part of the healthcare maintenance discussion for the pregnant woman with diabetes (ADA, 
2020). Diabetes education begins with setting clear goals for maintaining optimal blood glucose 
levels during pregnancy, clearly stating the maternal and fetal risks of hypo- and hyperglycemia, 
discussing lifetime risks associated with diabetes during pregnancy, expected pregnancy 
management and outcomes, and plans for delivery. 
The recommendation for women with insulin dependent preexisting diabetes in 
pregnancy is to check blood glucose at least seven times per day; for women with gestational 
diabetes the recommendation is to check at least four times per day, while both populations 





to consume the nutritional accepted daily recommended intake (DRI) for pregnancy (ADA, 
2020). Table 2 illustrates the ADA recommended guidelines during pregnancy. 
Diabetes During Pregnancy Practice Guidelines 
The American Diabetes Association publishes the Annual Practice Guideline for 
clinicians to use to enhance care for pregnant women with diabetes. Table 2 demonstrates the 
HbA1c and blood glucose targets recommended for pregnancy (ADA, 2020).The ADA 
recommends fasting and postprandial glucose monitoring during pregnancy, and that some 
women with preexisting diabetes or complicated gestational diabetes also test preprandial blood 
glucose, although there is no set target goal found. For women prescribed antihyperglycemics 
with multiple daily injections (MDI) or insulin pump infusion, the ADA recommends 
preprandial glucose monitoring and one-hour postprandial glucose monitoring for premeal rapid-
acting insulin adjustment. CGM use among women with chronic diabetes during pregnancy, in 
addition to standard care, demonstrate a mild improvement of HbA1c without an increase in 
hypoglycemia. The Medtronic Guardian and the Dexcom G6 are the two CGM devices that have 
received FDA approval for use during pregnancy. The Medtronic Guardian CGM uses the 
CareLink software for data upload, download, and interpretation. See Figure 1 for the Dexcom 
Clarity CGM software and Figure 2 for the Medtronic CareLink CGM software used for this 
review. See Table 3 for the continuous glucose monitoring device comparison. 
The American Diabetes Association (2020) recommends continuous glucose monitoring 
devices in conjunction with insulin therapy for adults with type 1 and type 2 diabetes. CGM 





safe for those with hypoglycemia unawareness. Further, CGM use improves A1c levels, time in 
range, and neonatal outcomes in pregnant women (ADA, 2020). 
Problem Description 
The implementation site was a subspecialty high risk obstetrical unit within a major 
Northern California healthcare maintenance organization. The unit provides care to high risk 
obstetrical patients referred by obstetrical providers and perinatologists throughout the region. 
The unit operates at an average daily census of nearly 2000 patients assigned to a core of eight 
registered nurse on dayshift and on evening shift to manage pregnancy complications such as 
preterm birth, hypertension, and diabetes. The number of women referred to the unit for 
management of diabetes during pregnancy has increased over time. In fact, the rate of women 
pregnant with pregestational diabetes during pregnancy increased 37%, while women diagnosed 
with gestational diabetes increased 56% from 2000-2010 (CDC, 2013). The registered nurses are 
assigned a daily list of patients to call for telehealth appointments. These appointments typically 
take 15 minutes to gather blood glucose data, review antihyperglycemic regimen, synthesize 
information and data, and develop a treatment plan.  
The unit operates 16 hours per day, seven days a week, and is open during all holidays. 
Each of the eight registered nurses typically have 20-25 patients to call during the shift. Patients 
referred to the unit were assigned a weekly telephone appointment. If a patient did answer the 
call during the appointment time, the registered nurse left a message, and rescheduled the patient 
within the shift when the patient called back. Women pregnant with chronic diabetes were 
referred when viability was confirmed by observed cardiac activity and when the fetal pole 





weeks (Gupta & Roman, 2019). From the first trimester, women spent an average of 28-36 
weeks enrolled in the program. Women diagnosed with gestational diabetes were enrolled 
between 24-28 weeks gestation and spent between 12-16 weeks on the program. 
The blood glucose status of women referred to the unit range from controlled, somewhat 
controlled, to uncontrolled. Most were currently using insulin, Glyburide, or minimal Metformin 
dosages to control their blood glucose at the time of the referral to the unit. Once enrolled in the 
program, the registered nurse educated the patient on diet, exercise, and lifestyle changes to 
better control their blood glucose. After one to two weeks on service, the registered nurse made a 
recommendation to the provider to optimize blood glucose control. The provider determined the 
treatment plan, scheduled a one-on-one teaching appointment with a clinical registered nurse, 
then sent a new medication order to the unit. The registered nurse subsequently and periodically 
titrated the antihyperglycemic medication based on a protocol that was approved by the 
leadership of the implementation unit. 
Some women with chronic diabetes or complicated gestational diabetes were referred to 
the unit with continuous glucose monitoring devices already in use. Prior to the pilot, the 
registered nurse sent blood glucose reports to the primary care obstetrical provider or to the 
perinatologist to make insulin adjustments rather than interpreting the data and adjusting the 
insulin dosage at the point of care. This practice delayed patient care, limited registered nurses 
from working at the top of their licenses and did not uphold the scope of practice outlined by the 
American Association of Diabetes Educators (2017). The AADE scope of standards guide 
diabetes educators’ practice, which include registered nurses as members of the diabetes care 





made widely available to clinicians such as nurses and nurse practitioners, without formal 
certification, as this adds barriers to CGM usage and isn’t necessary. Fonseca, et. al., (2016) also 
suggests clinician training be expanded to all clinicians who care for patients with diabetes. This 
pilot demonstrated CGM capabilities in a telehealth nursing unit, expedited patient care, and 
allowed the primary care provider to commit time to acute patients who needed to be seen in 
clinic. Prior to the pilot, no established standardization for utilizing CGM during pregnancy 
existed for nursing staff. CGM and diabetes management education ensured registered nurses in 
a telephonic nursing unit were prepared and competent making insulin dosage titration based on 
the CGM Time in Range report. Per discussion with the leadership of the implementation unit, a 
nurse practitioner-developed protocol for insulin adjustment was used for this project. See 
Appendix K and Table 1 for the insulin titration protocol. 
Available Knowledge 
PICOT 
Would nurses providing care to pregnant insulin-dependent women using CGM device 
technology, compared to pregnant insulin-dependent women receiving standard care, 
demonstrate increased confidence and competence when patients have a 50% decrease of 
hypoglycemic episodes within three weeks of starting the program? To answer the question 
about the reliability and accuracy of the continuous glucose monitoring time in range report used 
by registered nurses as a clinical decision-making aid, compared to the standard care provided to 
pregnant women with diabetes, a broad search of CINAHL Complete, Joanna Briggs Institute of 
EBP (first search and PubMed), and Scopus electronic databases using the search terms 





practitioner” yielded 113 articles. Subsequently, 59 filtered free full-text, abstract, clinical trial, 
random controlled trial, and systematic reviews published between 2010 to 2020 were accepted. 
After further review, the remaining 16 articles used were limited to the English language; articles 
that did not contain continuous glucose monitoring and pregnancy in the title, and articles 
without an abstract were removed. Exclusion criteria of CGM devices other than Dexcom G6 or 
Medtronic Guardian were applied because other devices used in the United Kingdom are not 
approved for use in the United States by the Federal Drug Administration. The common themes 
found in the reviewed articles were CGM therapeutic decision-making, CGM time in range 
report provides clear goals, CGM use lowers HbA1c levels, CGM use reduces diabetes-related 
complications, CGM education and training for nurses, and the role of the nurse practitioner. 
Appendix A details the review of evidence grid. 
CGM Guides Therapeutic Decision-Making 
 CGM is a safe and effective method to guide therapeutic decision-making for pregnant 
women with diabetes when placed on the upper arm. Reliable CGM results correlate with the 
self-monitoring blood glucose (SMBG) results, often detecting postprandial hyperglycemia, and 
nocturnal hypoglycemia better than SMBG testing alone. The Time In Range (TIR) report has 
been validated by multiple CGM clinical trials as a valuable tool for clinical decision-making 
about insulin adjustments and has been proven to predict blood glucose trends so that changes 
can be made in a timely manner (Castorino, Polsky, O'Malley, Levister , Nelson, Farfan, 
Brackett, Puhr,& Levy, 2020; Gabbay, et al, 2020; Mazze, Yogev, & Langer 2012; Polsky & 
Garcetti, 2017). The accepted glycemic variability range is 70 mg/dl to 180 mg/dl (ADA, 2020). 





diabetes. The Polsky & Garcetti (2017) study reported more values in the target range and 
provided more blood sugar values than women not using a CGM. The accuracy of the Dexcom 
G6 CGM to that of fingerstick blood glucose results (Castorino, et al., 2020) demonstrated CGM 
accuracy of 92.5% when compared to that of non-pregnant Dexcom G6 CGM users who placed 
the CGM on the upper arm. The study found the results of the Dexcom G6 CGM to be less 
accurate when placed on the abdomen, or buttocks of pregnant women with diabetes. These 
studies demonstrate that women with diabetes benefit from CGM device placement on the upper 
arm, which results in more accurate data for providers to base clinical decisions.  
CGM Time in Range Report Provides Clear Goals 
Time in range (TIR) is the optimal blood glucose level achieved without inducing signs 
and symptoms of hypoglycemia and has been correlated with less complications of diabetes. 
However, if patients are to be counseled to maintain blood glucose in the optimal range, 
registered nurses need to be trained to assess CGM data to make insulin adjustments. Eight 
articles offered similar definitions and rationales for selecting TIR as a valuable tool for clinical 
decision-making (Battelino, et al., 2019; Brown et al., 2019; Feig, et al., 2017; Gabbay et al., 
2020; Mazze, et al., 2012; Polsky & Garcetti, 2017;Vigersky & McMahon, 2019; Zaharieva, et 
al., 2020). The International Consensus in TIR advocates for the use of TIR reporting as a 
standardization for report glucose control and highlight the need to train clinicians and patients 
on how to access, interpret, and use CGM tools to answer questions about glycemic control and 
outcomes (Gabbay et al., 2020).  According to researchers, participants who showed a high TIR 
percentage indicated optimal glucose control and longer periods in the target range (Gabbay et 





requiring analysis by trained clinicians. The TIR report is the most widely accepted CGM 
download, most accurately measures blood glucose, and is relatively easy to interpret by trained 
clinicians. As a blood glucose monitoring resource, the TIR is a valuable tool used to identify 
nocturnal hypoglycemia when the patient displays nocturnal hypoglycemia unawareness (Brown 
et al., 2019). 
CGM Use Lowers HbA1c Levels  
CGM use is associated with lowered HbA1c levels within 3 months of intensive diabetes 
management or at the end of the pregnancy. The findings of the Advanced Technologies & 
Treatment for Diabetes Congress were commissioned to develop clinical CGM targets to be used 
by clinicians and others in interpreting reported CGM data (Battelino, et al., 2019). This study 
reported 31% of CGM users with lower HbA1c levels after 4-6 weeks of monitoring, and 
significantly lower HbA1c at 36 weeks gestation (Battelino, et al., 2019). The commission 
recommended 3 core metrics specifically targeting CGM use during pregnancy. The 3 metrics 
were identified as 1) percentage of blood glucose readings and time per day in the target range, 
2) time below the target range, and 3) time above the target range. The commissioned experts 
mutually agreed upon target percentages of TIR as the benchmark for making insulin 
adjustments for diabetes in pregnant patients. Evidence supporting the use of the TIR report 
show there is a strong relationship between percentage TIR and HbA1c when CGM results are 
compared to SMBG results (Vigersky & McMahon, 2019). In relation to the HbA1c levels of 
1,137 participants with type 1 or type 2 diabetes, researchers successfully demonstrated TIR 
without episodes of hypoglycemia was achieved by use of CGM during pregnancy and was 





(2019) review discovered that for every 10% change in TIR, study participants achieved an 
average 0.08% change in HbA1c. Likewise, Feig, et al. (2017) reviewed the risk of low 
percentage TIR in the Diabetes Control and Complications Trial (DCCT) data. The DCCT is an 
on-going, multicenter random controlled trial studying woman aged 18-44 who are <13 weeks 6 
days pregnant with type 1 diabetes. This on-going clinical study spans across England, Canada, 
Scotland, Spain, Italy, Ireland, and the U.S., and is designed to determine if intensive blood 
glucose concentrations kept as close to normal result in early vascular complications. 
CGM Use Reduces Risk of Diabetes-Related Complications 
The difference in TIR between those that develop eye or kidney disease and others is 
related to a decrease in TIR of approximately 2.5 hours per day in the acceptable range for those 
using CGM. In the Feig, et al., (2017) study, pregnant CGM users spent more time in target at 
68% than did the SBMG users who spent only 61% in the target range. This study concluded that 
TIR is strongly associated with risk of microvascular complications and can be used as another 
endpoint for clinical investigations, but further studies are needed. Another such example is the 
Beck, et al., (2018) review that reanalyzed the dataset of the DCCT study to search associations 
between TIR and development or progression of microalbuminuria or retinopathy. Using 545 
subjects with type 1 diabetes out of 1,440 DCCT participants, researchers looked at capillary 
measurements for one day every three months resulting in 32,528 quarterly data collections with 
seven patient profiles complete for 24, 892 datasets, and found 19% met the criteria for 
microvascular complications, while 9% met the criteria for microalbuminuria. Of the 1,440 
participants, CGM users improved TIR by 80% and reduced hypoglycemic events by up to 40%. 





myocardial infarction, end-stage renal disease, severe vision loss, and amputations, lowering 
overall healthcare costs by $6.7-$9.7 billion over 10 years. 
CGM Reduces Incidence of Hypoglycemia 
CGM users spend less time and have fewer incidents of hypoglycemia than SBMG users. 
CGM use among women with diabetes during pregnancy reduces incidents of hypoglycemia, and 
reduces the time spent with hypoglycemia symptoms. Hypoglycemia is defined as blood glucose 
<70 mg/dl, while severe hypoglycemia is defined as <54 mg/dl. Both terms are universally 
accepted (ADA, 2020). The goal of CGM is to identify episodes of hypoglycemia that otherwise 
would not be captured by self-blood glucose monitoring of fingersticks at certain points in time. 
CGM users are alerted 30-90 minutes of an impending hypoglycemic episode and can act before 
feeling signs and symptoms. Symptoms of hypoglycemia include confusion, sleepiness, 
tachycardia, diaphoresis, hunger, and irritability. CGM data can be accurately relied upon and 
can be used as an effective means to record nocturnal glycemia to make individual adjustments. 
Women with preexisting diabetes spend less time in hypoglycemia with continuous 
glucose monitoring. In a study of randomized pregnant and nonpregnant adults, participants 
showed a 48% reduction of nocturnal hypoglycemia, a 65% reduction of severe nocturnal 
hypoglycemia, and a 40% and 54% reduction in daytime hypoglycemia and severe 
hypoglycemia, respectively (Zaharieva, et al., 2020), but longer studies are needed to determine 
the longer-term effects of CGM device use. For example, Polsky & Garcetti (2017) found that 
participants who spent more time in the optimal glycemic range experienced less episodes of 
hypoglycemia. In an alternate study, women with gestational diabetes or preexisting diabetes 





percent of time spent in hypoglycemia for at least 3 days on the abdomen area. All subjects were 
treated with antihyperglycemics such as insulin, glyburide, or metformin during pregnancy. The 
3-day CGM results were compared to 31 non-pregnant women with preexisting diabetes during 
the same time period and resulted in less episodes of hypoglycemia (Mazze, et al., 2012). 
CGM Education and Training for Nurses 
Registered nurses are ideally positioned to provide education to people living with 
diabetes, however, registered nurses without formal diabetes education lack the knowledge to 
provide critical education to patients. Under direction and protocol of nurse practitioners, 
registered nurses who work with patients with diabetes would benefit from CGM training, 
intensive education and precepting on diabetes technology and management (Hollis, et al., 2014). 
With CGM training and education, registered nurses can address knowledge gaps using best 
practice guidelines and health promotion principles (Berget & Wyckoff, 2020). In the 51 U.S. 
nursing jurisdictions, registered nurse scope of practice is broad and allows for development and 
knowledge transfer. (Jones, 2015; Temple University, 2015). Nursing scope of practice allows 
for dependent function, authorizes direct and indirect patient care services, including the 
administration of medications and therapeutic agents necessary to implement a treatment ordered 
by and within the scope of licensure of a physician (CA Board of Registered Nursing, 1995). 
Nurses use skills that build on traditional models of collaborative care, promoting rapid uptake of 
integrative technology, and support a broader context of the nursing process of assessment, 
planning, implementation, and evaluation of the whole patient (Jones, 2015). Registered nurses 
who specialize in diabetes management enhance opportunities for chronic-disease self-





CGM as adjunct therapy to multiple daily injections enhance diabetes control during pregnancy. 
Utilizing the diabetes educator nurse leads to better outcomes and reductions in the risk for long-
term complications (Jones, 2015).  
CGM Certification 
 The Association of Diabetes Care and Education Specialists (ADCES) launched a new 
CGM certificate program for those working in diabetes management to improve clinical 
outcomes for people who use CGM technology (ADCES, 2019). The certification program is 
voluntary and not required for practice in diabetes management. Access to the certificate 
program is free for ADCES and American Association of Diabetes Educators (AADE) members. 
Enrollees receive a certificate and earn up to 14.50 continuing education credits for completing 
the online program, which can be applied toward registered nurse license renewal (ADCES, 
2019). 
CGM in Practice 
 Registered nurses care for patients using CGM in many different practice settings. The 
US Food and Drug Administration has approved CGM for use in the school settings where over 
50% of children with type 1 diabetes under the age of 18 use CGM technology. School nurses 
rely on guidance from the American Diabetes Association (ADA, 2020) Safe at School education 
and training tools on continuous glucose monitoring. The ADA offers courses designed to assist 
school nurses with valuable information to reduce the burden that diabetes has on children in 
school. The recommendations for use of continuous glucose monitors in the school setting offers 





As an example, in other areas of practice, school nurses are part of the healthcare team 
for students attending school with type 1 diabetes and who use CGM (Berget & Wyckoff, 2020). 
With the increasing use of CGM among adolescents with type 1 diabetes, school nurses play a 
vital part in caring for these students and must be comfortable providing care to support CGM 
use during school hours. In addition to glycemic control management, school nurses must 
receive education related to CGM devices, calibration requirements, and related reports and 
trends. In collaboration with the primary care provider, the school nurse provides diabetes care 
management to ensure optimal growth and development of the adolescent in her care. For 
example, school nurses receive training to recognize arrow trends on CGM devices to predict a 
rise or fall of a student’s glucose level, and utilization of the data-sharing capabilities to remotely 
monitor blood glucose levels, minimizing frequent education interruptions while the student is in 
class (ADA, 2020). 
Nurses are in a unique position to educate interdisciplinary staff, patients and their 
families by being an extension of the care patients receive in the clinic by the primary care 
provider. In a separate study that measured nurses knowledge related to diabetes education and 
training for nurses, Hollis, Glaister, & Lapsley (2014) found registered nurses received average 
scores on basic diabetes management principles but scored significantly higher than average after 
received additional CGM and diabetes education and training. In a follow-up questionnaire, 
registered nurse qualitative data indicated increased confidence and competence in managing 
people with diabetes (Hollis, et al., 2014). 
Role of the Nurse Practitioner 





management of patients with diabetes. Nurse practitioners promote self-management, decision 
support, and delivery system design. Patient education by nurses and nurse practitioners improve 
the percentage of patients reaching metabolic targets. In a study measuring outcomes of patients 
receiving diabetes education from a nurse practitioner-run clinic, one single visit with a diabetes 
specialist nurse improved HgbA1c at 6 months with continued improvement to one year (Kruger, 
2012). In a retrospective, cross sectional design study, patients with diabetes received specific 
interventions according to a predetermined protocol. The clinic nurse performed the treatment 
management by following the American Diabetes Association guidelines and followed patients 
for 25 months. The clinical nurse gave personal counseling and educated patients about the 
disease process and control, diabetes management targets, and follow up clinic visits during 
telephone appointments. As a result of the nursing interventions, the patients’ blood glucose 
showed a marked improvement (Ginzberg, et al., 2017). 
Rationale 
The Change Theory of Nursing is the basis of this paper’s theoretical framework. The 
nursing theory was developed by Kurt Lewin to explain the phenomenon of overcoming 
resistance to change. The three major concepts of the Change Theory are driving forces, 
restraining forces, and equilibrium. Driving forces are those that facilitate change, leading to the 
desired results. The driving force shift a change in the equilibrium. Driving forces and restraining 
forces push change in the opposite direction, leading to a hinderance of change and an 
equilibrium that oppose change. Equilibrium can be altered by the changes that occur between 





The three stages of the nursing theory are unfreezing, change, and refreezing. Unfreezing 
involves utilizing a method to encourage the release of the old way of getting things done that 
are not productive. Many patterns in nursing can be improved by fostering an environment that 
promotes group conformity. This is achieved by increasing the driving forces that oppose the 
existing situation. Decreasing the restraining forces that contribute to disequilibrium and 
combing the increasing driving forces with the decreasing restraining forces is the process of this 
framework (Kaminski, 2011). The premise of Lewin’s Change Theory helps to explain the 
phenomenon of registered nurses being reluctant to adjust insulin dosages for pregnant women 
who use continuous glucose management devices as adjunctive therapy even though it is within 
the scope of their practice, and the policy and procedure exists to help them carry out procedures 
safely. CGM use in pregnancy effectively identifies low blood sugar so that insulin dosages can 
be adjusted by registered nurses, thus expediting care, increasing patient safety, adequately 
controlling blood glucose, eventually restoring the counterregulatory hormone response, and 
improving patient awareness overtime (Tkacs, 2002). See Figure 3 for Lewin’s Theory of 
Change. 
Specific Aim 
This project changed clinical practice by providing a clinical decision-making tool 
for registered nurses, improved the blood glucose of pregnant women who use CGM 
during pregnancy, provided the registered nurse with a provider-developed insulin 
titration protocol that quickly identified blood glucose trends, such as hypo- and 
hyperglycemia, eliminated the delay in care and improved the care that registered nurses 





the registered nurses felt empowered to take swift action to make insulin adjustments 
using the new insulin titration protocol, thereby reducing the of rate of hypoglycemia for 
pregnant women who use CGM during pregnancy by 50% in the first 3 weeks of the start 
of the pilot. See Appendix K for the provider-developed insulin titration protocol. 
Lewin’s Theory of Change 
Lewin’s Theory of Change was the basis of the three-step process to effectively 
implement the provider-developed protocol. The first step of unfreezing began with the 
initial needs assessment conducted to identify the gap in patient care provided to pregnant 
women who use CGM during pregnancy. The previous practice of forwarding collected 
blood glucose data to the provider who then made insulin adjustment recommendations 
delayed care and allowed for continued risks of hypo- or hyperglycemia events. The 
second step of Lewin’s Theory of Change occurred during the education and training on 
CGM technology use during pregnancy, Time in Range report interpretation, review of 
the provider-developed insulin titration protocol, and professional CGM documentation 
and communication with the primary provider. The final step of Lewin’s Change Theory 




Assessment of the CGM technology interest, current nursing knowledge gap of 
CGM device technology and report interpretation was necessary to determine the level of 





accomplish this goal, the nursing staff completed a knowledge-based assessment on CGM 
clinical use and decision-making which was the basis for the nursing CGM education. 
This initial assessment also determined the level of interest for the pilot project. Prior to 
the CGM education, the registered nurses took a pretest to measure CGM competency, 
while the post-test assessed the efficacy of the CGM training.  
Intervention 
The intervention was the development of continuous glucose monitoring education 
modules based on best practices. The intervention was chosen by this DNP candidate to improve 
the registered nursing staff’s skills regarding pregnant women with diabetes management using 
continuous glucose monitoring. The goal of the education modules was to increase registered 
nurse knowledge on how to manage blood glucose of pregnant women with diabetes who use 
CGM device technology. Secondary goals of the education modules were to decrease episodes of 
hypo- and hyperglycemia, to safely decrease HbA1c levels during pregnancy, and to increase the 
number of referred patients utilizing CGM device technology. The education modules included 
PowerPoint slides on CGM devices and report interpretation for clinical decision-making. 
The education modules included case studies to guide clinical decision-making. The 
modules also included evidence-based practice guidelines provided by the American Diabetes 
Association, CGM education and training principles of the Association of Diabetes Care and 
Education Specialists, CGM device manufacturer user guides, and a review of the new insulin 
titration protocol. Pictures of CGM reports, trends, and blood glucose values were reviewed. The 
PowerPoint slides were reviewed by the student nurse practitioner who has experience using 





departmental leadership reviewed the guidelines and parameters by which registered nurses 
provided patient care. Registered nurses called patients weekly to review CGM Time in Range 
(TIR) report, assess dietary intake and physical activity, and titrated insulin dosages based on 
CGM Time in Range report interpretation using the new protocol. Management participated in 
the review and development of guidelines and parameters based on the American Diabetes 
Association clinical practice guidelines, Medtronic Guardian CGM and Dexcom G6 user 
manuals by approval of institutional leadership. A team of registered nurses were recruited to 
assist with CGM education and evaluation of the nursing staff. The project team used Microsoft 
Teams to communicate progress on their individual contribution, needs, and requests to ensure 
the project was completed within budget and on time. The project benefited all insulin-dependent 
diabetes patients currently utilizing CGM device technology during pregnancy in the Northern 
California healthcare maintenance organization region. 
Continuous Glucose Monitoring Training 
Registered nurses completed four online training modules on CGM device technology 
and reporting software interpretation. Module one reviewed the Medtronic Guardian CGM 
device and CareLink software basics, the Dexcom G6 CGM device and Clarity software basics, 
CGM terminology, blood glucose report selection, and blood glucose report interpretation. 
Module two discussed CGM documentation and communication of reporting data to providers 
and methods for sharing data with interdisciplinary team members. Module three introduced the 
new insulin titration protocol for patient’s using multiple daily injections. Module four provided 





blood glucose data and apply the new CGM protocol to titrate insulin for pregnant women with 
diabetes. See Appendix J for an explanation of the online training modules. 
Study of the Intervention 
GAP Analysis 
After reviewing local resources, infrastructure, and processes, there was no program 
available to provide care for insulin-dependent women using CGM during pregnancy. The 
current practice of deferring insulin titration for pregnant women using CGM device technology 
during pregnancy to the perinatologist delayed patient care and limited the registered nurse from 
working at the top of their licenses. A second gap was identified that involved the variances in 
insulin-dependent diabetes education of the nursing and interdisciplinary staff. For example, 
when providing standard care to pregnant insulin-dependent women, some nurses titrated insulin 
up to the maximum dose allowed within the protocol (20%), but some nurses were more 
conservative and titrated insulin near the minimum dose (10%). This flexibility within the 
existing protocol was not evidence-based, nor did it fit the diabetes management protocol for 
provision of safe, high-quality diabetes care across the continuum of care, and could not be the 
basis of the CGM device and diabetes management project. The conservative approach to 
insulin-based care was based on fear of the unknown in terms of risks associated with 
hypoglycemia and a lack of confidence on behalf of the nurse. (See Appendix B).  
Stakeholders 
The stakeholders were management, leadership, physicians, advanced practice clinicians, 
and registered nurses. Management was a major stakeholder with significant influence, high 





keep the project on track. Institutional leadership was a stakeholder of high influence, high 
impact and importance, with the ability to contribute or block the project, and took minimal 
engagement to keep the project on track. Physicians were stakeholders with some influence, low 
impact and influence, but of high importance, with some contribution, with no ability to block 
the project, and took little engagement to keep the project on schedule. Lastly, registered nurses 
were key stakeholders of high impact, importance, and influence who made high contributions, 
with no ability to block the project, requiring a significant amount of engagement to keep the 
project on schedule. (See Appendix C). 
SWOT Analysis 
The SWOT analysis project management tool identified areas of improvement, provided 
information to the project manager, ensured the project was completed on time, within budget, 
and helped to alleviate risks associated with tasks (Lim, 2012). The SWOT analysis for the CGM 
and Diabetes Management project identified several strengths, weaknesses, opportunities, and 
threats, which are described below. 
Strengths 
The strengths associated with the CGM and Diabetes Management project included 
increased confidence and competence among the registered nurses, expediency of care provided 
to patients using CGM technology, increased patient safety by decreasing in the number 
hypoglycemic episodes which was a provision of the 16-hour nursing support system, and the 
utilization of SMART goals in the project management of the assigned tasks. Expediency of care 





risk by offering a seamless delivery of care through integration, coordination, and utilized the 
interdisciplinary team approach in project management. 
Healthy People 2020 identified patient safety and quality as a leading health indicator and 
provided an evidence-based resource summary on improving the outcome of pregnancy and 
enhanced perinatal health through quality, safety and performance initiatives 
(healthypeople.gov). This resource provided the evidence necessary for offering 16-hour nursing 
support to vulnerable populations. SMART goals utilization was identified as a strength because 
when referenced in relationship to project management, the ability to successfully achieve goals 
was enhanced.  
Weaknesses 
The weaknesses were identified as the variability of CGM and diabetes management and 
insulin titration by the nurses, patient compliance with weekly phone calls, lack of an increase in 
patient census, and the limited supporting evidence in the literature because a project proposal of 
this type was unprecedented. Patients were less likely to adhere to nursing advice when 
historically, care was provided by perinatologists or diabetes endocrinologists. Patients typically 
did not answer the registered nurse’s call when trust was not established or when patient’s felt 
the service was not beneficial because the nurse was unable to titrate insulin dosages based on 
the CGM reports. Expanding the diabetes management during pregnancy program to CGM users 
was hypothesized to inversely increase the patient census when the project was supported by 
institutional leadership; however, this did not occur. Lastly, the lack of supporting evidence in 
the literature due to the unique nature of this project was a weakness when information was 






The opportunities were reduced hypo-and hyperglycemic episodes, increased patient 
safety, enhanced clinical decision-making, increased confidence and clinical competence among 
the registered nurses, garnered institutional leadership and provider support, the utilization of 
interdisciplinary teamwork, program recognition and modeling, a service provided to a 
vulnerable population, and the utilization of evidence-based standards. The implication for 
change varied and served many purposes. Implementation of this project eased congestion in the 
clinic and garnered perinatologists’ support. As this project provided a valuable service to a 
vulnerable population by utilizing evidence-based standards and provided recognition to the 
institution as a model for other healthcare systems to follow in the future. 
Threats 
The perceived threats to the CGM and Diabetes Management project included resistance 
from the registered nurses, lack of sponsor support, provider resistance, and pushback from 
competing subspecialty units. The threat that was most anticipated was resistance from registered 
nurses. This threat was highly expected because registered nurses expressed concern with the 
increased work involved with previous projects. Registered nurses were resistance to change and 
voiced opposition to the increased responsibilities and workload as they learned a new practice 
care delivery system. However, with transparency, clear communication, and adequate training, 
this threat was overcome. 
Provider resistance was expected from providers who lacked knowledge of the unit’s 
expertise in perinatal glucose monitoring, lack of project objectives, and lack of understanding 





clinics were anticipated because they perceived the project was taking responsibilities and 
patients away from the services they provided. One such subspecialty clinic was the Diabetes 
Clinic, which operates at major hospital satellites in the perinatology clinics throughout the 
healthcare institution’s Northern California region. These subspecialty clinics operate 
independently of each other and often did not refer their most complicated pregnant insulin-
dependent patients using CGM unless care involved only routing collected blood glucose data 
from the patient to the Diabetes Clinic. 
However, with education on the benefits of the project, which closed the CGM and 
diabetes management gap, the perinatologists in the Diabetes Clinics realized the CGM and 
Diabetes Management During Pregnancy project provided quality, safe, evidence-based care. 
Lastly, the lack of sponsor support threat was evident by resistance from the registered nurses 
and providers, and pushback from competing subspecialty clinic perinatologists that eventually 
were overcome. (See Appendix D). 
Work Breakdown Structure 
The Work Breakdown Structure (WBS) provided a breakdown of all the steps of the 
project. The Continuous Glucose Monitoring and Diabetes Management During Pregnancy 
program consisted of five phases. Phase One was the initiation phase where meetings with 
leadership and management took place to discuss the project proposal. Phase Two involved the 
planning phase of the project. The project manager worked closely with management to select 
key team members and oversaw the development of the kick-off meeting. Phase Three occurred 
in conjunction with the first step of Lewin’s Theory of Change of unfreezing, and involved the 





titration protocol of the project with institutional leadership and management using ADA clinical 
practice guidelines, and CGM device user manuals. Phase Four, also step two of Lewin’s Theory 
of Change, initiated the registered nurse education and training on CGM technology and report 
interpretation. Phase 5 and step three of Lewin’s Theory of Change began with the 
implementation of the project pilot, analysis, discovery, acceptance of results and ultimately 
archiving of data. (See Appendix E). 
Budget 
The budget was based on the salaries of the registered nurse’s hourly wage. The 
education meetings took place during Microsoft Team meetings prescheduled with the 
assistance of management and the project manager. Microsoft Teams provided a platform 
to meet regularly, within strict timeframes, with limited costs, and by continued 
adherence to the social distancing policy currently in place. The average hourly wage for 
a registered nurse was $77.00 per hour. There were 36 registered nurses who were invited 
to participate in the education meetings. The total for all training sessions was budgeted 
at $2772.00, however due to the COVID-19 temporary work from home policy change, 
the nurses completed the CGM education and training modules at home independently. 
This ultimately cost the unit zero dollars. (See Appendix F for the estimated budget prior 
to the COVID-19 temporary work from home policy enactment). 
Communication Plan/Matrix 
Microsoft Teams was used as the communication board method of communication 
between the project manager, leadership, and team members. The supervising faculty 





DNP Statement of Non-Research Determination Form (see Appendix G). The 
communication board was customized for each team member, improving communication 
board utilization and reporting. The communication board ensured that each team 
member knew their responsibility, held each team member accountable, and provided 
transparency for leadership. Leadership was well informed of the scope of the project, the 
timeframe for completion of the project, accurate costs of the project, met stakeholder’s 
expectation by displaying push back from the project manager. Transparency provided  
accuracy and led to improved decision-making. Communication board reporting was an 
important concept of the project management. The benefit of current, accurate, and 
relevant communication board reporting required that updates were completed daily 
because it held team members accountable for the scope, time, and costs of the project. 
One of the benefits of utilizing communication board reporting was the customization to 
each individual team member’s needs. Therefore, team members only needed to access 
areas of the communication board that related to their individual contribution, as all team 
members were well informed of progress during weekly Microsoft Team meetings. To 
mitigate planning and decision-making, weekly Microsoft Teams meetings were held to 
bring all team members together for discussions related to data collection and fulfilled 
request for feedback from stakeholder and team members. Weekly Microsoft Team 
meetings provided opportunities to ask important questions and overcome obstacles.  (See 








To measure outcome goals, this project used the SMART goal template. The 
specific goal of educating the training the registered nurses for required analyzing their 
level of readiness and education. The resources to provide the education were created. 
Each registered nurse was equipped with a computer, Microsoft Teams access to facilitate 
communication, and management support for the pilot.  
The primary measurement tool identified for this project was the qualitative data 
retrieved and analyzed from the Qualtrics pre- and post-surveys given to the registered 
nurses upon completion of the four modules. The secondary outcome measures were the 
HgbA1c <7.0 percent and 50% reduction of hypoglycemic episodes  of patients referred to 
the program. The specified goal of safely improving patient glycemia and expanding 
diabetes management to include CGM knowledge would empower the registered nurses 
to care for this population, and accurately adjust insulin dosages using the CGM device 
reports along with the glucometer blood glucose readings.  
The goal to improve glycemic control during pregnancy using CGM device 
technology while also reducing episodes of hypoglycemia was attainable. After 
assembling a team to work together to identify potential pilot participants, patients 
eventually were referred to the unit and assigned to a registered nurse for weekly 
telephone appointments. This contact required no special equipment of expenditures for 





Relevancy of the stated goals was determined because the strategy for e-learning 
fit within the current temporary work from home policy as a result of the COVID-19 
pandemic. The defined goals are time based because the training and education the 
registered nurses received now allows them to take immediate action when identifying 
abnormal glucose values on the CGM report. 
Each nurse who agreed to participate in the pilot understood the end date for 
achieving the goals and understood the time and structure of the pilot. Once Northern 
California HMO members were referred to the implementation unit with a confirmed 
IUP, the registered nurses applied the learned CGM technology, diabetes during 
pregnancy support, and medication titration protocol via weekly telephone appointments. 
It is of my opinion, and the reason for the pilot project, that the implementation unit 
could do more to provide care to insulin-dependent women who use CGM device 
technology. This can be accomplished by interpreting Time in Range reports and titrating 
insulin dosages when hypoglycemic episodes are identified. It is possible to reduce 
HgbA1c levels safely during pregnancy by using the ADA recommended guidelines. 
Prior to enrollment, members had a baseline HbA1c drawn, and subsequent levels drawn 
each month until delivery or at the end of the pilot, whichever came first. The timeline 
for the pilot project was for a maximum of twelve weeks. These goals were realistic and 








Qualtrics was used to provide gap analysis, and pre- and post-surveys. The 
registered nurses were given a gap analysis survey to determine their CGM device 
technology and report interpretation educational needs. Information gathered from the 
Qualtrics were used as the basis for the continuous glucose monitoring blood glucose and 
CGM report interpretation training modules. After CGM training, registered nurses took a 
posttest to measure hypo- and hyperglycemia trending and recognition, appropriate blood 
glucose report selection and data interpretation. Efficacy of continuous glucose 
monitoring training, and the knowledge gap assessment was measured by comparing the 
pretest and posttest results. Based on the outcome answers, education targeted the needs 
of the registered nurses and was be beneficial during the pilot. Lastly, the post-test 
measured the level of understanding of the education provided. Any information that was 
not understood or required remediation was evident on the post-test survey. See 
Appendix I for the Qualtrics pre-test survey. 
Ethical Considerations 
While the goal of this project proposal was to provide information and data 
supporting the need to provide quality care to a vulnerable population, leadership based 
their decision-making on qualitative and quantitative analytics. The primary objective 
was to increase the knowledge of the registered nurses in CGM device technology. 
Evidence supports the on-going education of clinicians who manage the blood glucose of 





project as it was a quality improvement project that changed practice to provide better 
care for patients. See Appendix G for the DNP SOD form. 
In the Jesuit tradition at USF, we are taught just as the Lord taught Cain in Genesis 4:9 
about the role of honesty and respect in our lives. When the Lord asked Cain where Able was, 
Cain responded “Am I my brother’s keeper?” As a nurse, the answer is a resounding “Yes!”. The 
American Nurses Association Code of Ethics encompasses three provisions that specifically 
apply to this project: Provision 3.4 explains professional competence in nursing practice, 
Provision 5.5 further encourages maintenance of competence and professional growth, and last, 
Provision 7.2, which details contributions through developing, maintaining, and implementing 
professional practice standards in the nursing profession. This project accomplishes and adheres 
to all the aforementioned provisions and in the spirit of the Jesuit teachings at the University of 
San Francisco’s School of Nursing and Health Professions.   
Results 
CGM and Diabetes Management During Pregnancy Pre-Education Survey 
 The CGM and diabetes management during pregnancy pre- and post-education and 
training surveys were created for this project using Qualtrics. The pre-education and training 
survey consisted of six questions and was sent to 30 registered nurses in the unit to determine the 
level of interest for the pilot project. Of the 30 registered nurses, nine completed the survey 
before the start of the pilot, nine didn’t respond, five declined to take the survey but verbalized 
their interest in the CGM and education and training modules, four retired before completing the 





one went on medical leave of absence and did not complete the pre-education and training 
survey. See Appendix M for the post-education and training survey. 
CGM Education and Training Modules 
Four modules were created to educate the registered nurses on CGM technology and to 
training them on the NP-developed insulin titration protocol. Module One introduced CGM 
devices used during pregnancy, recognition of two CGM devices, instructed on accessing CGM 
software websites for viewing CGM data and reports, understanding basic CGM terminology, 
including how CGM works, appropriate blood glucose report selection, and interpret blood 
glucose reports to aid in clinical decision-making about insulin titration. 
Module Two established the agreed upon professional documentation and data sharing 
requirements for CGM and diabetes management. The professional documentation standards 
were agreed upon during the Advanced Technologies & Treatment for Diabetes Congress 
commissioned by leading experts in 2016 and affirmed in 2019 (Battelino, et al., 2019). The 
module explained professional CGM documentation, application of the knowledge of 
professional CGM standards to documentation in the HER, developing simplistic weekly 
goalsetting for patients, and communicating appropriate recommendations to providers. 
Module Three introduced the NP-developed insulin titration protocol and a new practice and 
procedure for the pilot project. The NP-developed protocol is based on prior ACOG and ADA 
guidelines used to develop the existing insulin titration protocol approved for patients referred to 
the Home Glucose Monitoring Program. This protocol is referred exclusively for pregnant 
women with diabetes who are referred with CGM during pregnancy, and who control their blood 





acting insulin such as Regular insulin, and intermediate-acting insulin such as Humulin-N, or 
NPH. The protocol was developed to assist providers who refer patients using CGM with the 
expectation that registered nurses will titrate insulin based on daily fingersticks for fasting blood 
glucose, and 1-hour postprandial for breakfast, lunch, and dinner. However, CGM allows the 
registered nurse to view blood glucose that is collected every 5 minutes, for up to 255 blood 
glucose values in 24 hours, viewable on the CGM software website. The NP-developed protocol 
uses the patient’s BMI to titrate insulin dosages based on increases or decreases of 10-20% of the 
previous insulin dose. 
In Module Four, registered nurses identified CGM devices, accessed the correct CGM 
software website, selected the appropriate blood glucose report, interpreted blood glucose reports 
in comparison to the SMBG, discussed lifestyle, dietary, and medication management causes for 
hypo- or hyperglycemia, set simplistic weekly blood glucose goals, transcribed professional 
documentation for sharing with providers. Module Four discusses continuous glucose monitoring 
and diabetes management during pregnancy by practicing CGM management in a case study 
format. See Appendix J for the four education and training module topics. See Appendix L for 
the Module PowerPoint slides. 
CGM and Diabetes Management During Pregnancy Post-Education Survey 
 Of the remaining staff, 23 registered nurses were invited to participate in the four 
education modules and complete the post-education survey. At the time of this paper, 17.4% of 
the registered nurses completed the post-education survey although 52.2% of respondents 
completed all four modules and began using the new protocol in practice during the pilot. Survey 





100% reported the graphics and module transcripts enhanced their learning, 50% reported their 
knowledge of CGM and diabetes management during pregnancy increased since completing the 
CGM education and training modules, 100% felt confident providing care to patients using 
multiple daily injections and CGM as adjunctive therapy after completing the CGM modules, 
and 100% reported a clear understanding of the NP-developed CGM insulin titration protocol 
after completing the CGM education and training modules. See Figure 4 and Figure 5 for 
statistical data. 
CGM and Diabetes Management During Pregnancy Pilot 
 Pilot participants were selected based on referral criteria from the primary obstetrical 
provider. Qualified participants were selected starting in June 2020 due to the limited number of 
CGM users during pregnancy in the region. At the time of enrollment, the participants ranged 
from eight weeks to 13 weeks gestation and were enrolled for an average of 16 to 25 weeks. 
Three patients were induced at 38 weeks gestational age in accordance with ACOG guidelines. 
The referral criteria are confirmed pregnancy viability, enrollment HgbA1c, glucometer and 
supplies, dietary consultation with a registered dietician, smartphone or CGM receiver, CGM 
device, basal insulin and preprandial insulin prescription with refills available. The pilot 
participants were asked to give the login information for the CGM device platform for weekly 
review during the telephone appointments. The patients were scheduled for weekly telephone 
appointments with the registered nurses to review multiple daily injection (MDI) blood glucose 
values to compare to the CGM sensor glucose values. If the patient did not answer the phone for 
their scheduled telephone appointment, the primary obstetrical provider was notified of the 





voicemail or secure message sent by the registered nurse. After three weeks of non-engagement, 
the patients would then be discharged from the pilot and program. 
In 2020, a total of 10 patients using a CGM device as conjunctive therapy with diabetes 
management were referred to the program. Nine of the 10 patients were pregnant and were 
enrolled in the project pilot. One patient was referred to the program but was not included in the 
pilot project because she was not currently pregnant, although she was prescribed a CGM device 
for use in the preconception counseling program. The registered nurses assigned to her 
management plan participated in the CGM education and training modules and reported positive 
responses on the post-education and training surveys. 
Overall, three patients enrolled in the pilot completed the program and delivered healthy 
infants, three are still pregnant and enrolled in the program, and three were discharged from the 
program due to non-engagement. Non-engagement is defined as three consecutive weeks without 
contact with the registered nurses and is a departmental policy requirement. Once discharged 
from the pilot and the program, the patients were referred to the primary obstetrical provider for 
continued coordination of care. These patients will be offered re-enrollment in the program when 
they are ready to be reinstated. 
Nursing Interventions 
 The four options of nursing intervention were 1) none needed, 2) registered nurse 
adjusted insulin using the NP-developed insulin titration protocol and routed to the obstetrical 
provider for review, 3) registered nurse routed to obstetrical provider for insulin adjustment 
recommendations based on patient concern, and 4) registered nurse adjusted insulin using the 





provider for additional adjustment greater than the protocol allows. See Appendix K and Table 1 
for the NP-developed insulin titration protocol. 
Starting Average Hemoglobin A1c 
The highest starting HgbA1c was 9.8% while the lowest was 4.7%. As a departmental 
policy, patients complete the HbgA1c lab test monthly. All participants successfully completed 
this requirement as ordered. Of the patients who successfully continued the pilot for the duration 
of their pregnancies, all showed improved HgbA1c except one. The average starting HgbA1c 
was 7.23% while the average final HgbA1c was 5.83%. While a decrease in HgbA1c was 
expected, as the literature supports, the speed at which the benefits of CGM during pregnancy 
became evident was a surprise. The pilot demonstrated a decrease of 1.4 percentage points in 
HgbA1c for these women. See Figure 6 for graphical data. 
Hypoglycemia 
 Two of the nine participants had a history of regular hypoglycemic episodes prior to 
enrollment. One of the two participants experienced severe hypoglycemia requiring 
hospitalization prior to pregnancy, complicating diabetes management due to extreme 
hypoglycemia unawareness and an increased risk of nocturnal hypoglycemia. 
Two of the nine participants experienced daytime hypoglycemia during the first two 
weeks enrolled in the pilot related to skipping the mid-morning snack and increased physical 
activity. These episodes were captured on the CGM report and immediately corrected by the 
registered nurse after decreasing the morning basal insulin. The intervention was based on the 





In total, all nine CGM and diabetes pilot participants reported zero episodes of 
hypoglycemia for the duration of the pilot after receiving education from the registered nurses on 
CGM report interpretation and after the CGM alarm settings were changed in accordance with 
ACOG and ADA recommendations for CGM use during pregnancy. Hypoglycemia avoidance 
was discussed at each weekly telephone appointment. 
Secondary Outcome Measures 
 The secondary outcome measures were related to maternal and fetal wellbeing. Although 
these two components of care were not intended as a primary measurement during the pilot, 
literature identified the need for ongoing research to establish them as primary outcome 
measures. As a result of close surveillance of blood glucose with MDI, glucometer blood 
glucose, and CGM sensor glucose, maternal outcomes revealed two of the three pilot participants 
who delivered did so vaginally. All three infants were delivered with a normal fetal weight of 
less than 4,000 grams as recommended by ACOG, and none required neonatal intensive care unit 
admission for hypoglycemia. One pilot participant delivered via cesarean section due to 
complications of preeclampsia that was unrelated to the CGM and diabetes management during 
pregnancy care received during the pilot. 
Final Average Hemoglobin A1c 
 All but one patient showed a decrease in HgbA1c by the end of the pilot or at delivery. 
The final average HgbA1c was 4.49% among the pilot participants. The HgbA1c improvement 
score was calculated by subtracting the starting average HgbA1c from the final HgbA1c for a 





successfully implementing the NP-developed insulin titration protocol without inducing signs or 
symptoms of hypoglycemia. See Figure 4 for the hemoglobin A1c comparison. 
Discussion 
Summary 
The specific aim of the pilot was to reduce the of rate of hypoglycemia for pregnant 
women who use CGM during pregnancy by 50% in the first 3 weeks of the start of the 
pilot. Further, the goal of reducing the HgbA1c level at the end of pregnancy or the end 
of the pilot was also achieved, improving maternal and fetal outcomes as an unintended 
secondary measure. Evidence is compelling and strong that registered nurses should be trained 
to use CGM device technology. With training, registered nurses work within their scope of 
practice to use CGM device technology along with a provider-developed protocol when caring 
for this population. The evidence contributes to the advocacy that all pregnant women with 
diabetes should have access to a CGM device to reduce the burden of diabetes on pregnancy, but 
more studies are needed to determine long term benefits and neonatal and maternal outcomes. 
Interpretation 
As evidenced in the studies examined for this pilot, there were no established 
standard of care utilizing CGM technology and preprandial blood glucose goals. The 
ADA’s postprandial blood glucose recommendations, in conjunction with clinical CGM 
targets developed by the Advanced Technologies & Treatment for Diabetes Congress 
provide some evidence that CGM can improve BG control, limit blood glucose variab ility 
by allowing early intervention, reduce episodes of hypo- and hyperglycemia, and is safe 





Although standardized procedures utilizing CGM are needed for nurses taking care of 
pregnant women with diabetes, no such established standardization existed prior to the pilot. The 
pilot evidence indicates that CGM can help achieve an adequate HgbA1c when used as adjunct 
therapy with self-management blood glucose (SMBG) without increasing the risk of 
hypoglycemia during pregnancy. CGM greatly reduces the burden of diabetes during pregnancy 
by reducing the number of fingersticks required to accurately and safely titrate insulin. CGM is a 
reliable method for making clinical decisions about insulin and glycemic goals. CGM use has not 
been associated with adverse outcomes during pregnancy and reduces the lack of hypoglycemia 
awareness by accurately predicting hypoglycemia by up to one hour before an occurrence. 
CGM can accurately identify low blood glucose trends, can be used effectively in 
conjunction with standard care during pregnancy to aid in the treatment of diabetes in pregnancy. 
The reviewed articles share the common conclusion that CGM data accurately report blood 
glucose values when compared to SMBG data. The literature recommends CGM as adjunct 
therapy for identifying and correcting hypo- and hyperglycemia, found comparable 
outcomes to women without diabetes during pregnancy, and used the same blood glucose 
target goals of 70 mg/dl to 180 mg/dl as recommended by the American Diabetes 
Association. The pilot adopted the literature evidence in the clinical decision-making tool that 
was also part of the innovative protocol for insulin titration used by the registered nurses. 
Several articles specifically advocated for registered nurses to be trained on report 
interpretation of CGM devices, and highlighted barriers to expanded CGM use due in part to lack 
of diabetes specialist education and training (Battolino, et al., 2019; Fonseca, et al., 2016; Hollis, 





article discussing the Advanced Technologies & Treatment for Diabetes Congress that was 
commissioned to develop clinical CGM targets (Battolino, et al., 2019). This article was used as 
a basis for developing a protocol to guide clinical decision-making because it compared two of 
the most common CGM devices, the Medtronic Guardian and the Dexcom G6 (see Table 3). 
Researchers (Battolino, et al., 2019) suggested clinicians and patients be trained to accurately 
interpreter the time in range report to make clinical decisions and insulin titration. The intent of 
the panel was to provide clinicians with the metrics needed to obtain and interpret current blood 
glucose levels and adjust therapy accordingly. 
Limitations 
The limitations of the project were the small sample size of the cohort, limited 
participation of the registered nurses, the limited timeframe of the pilot, and non-engagement of 
three of the nine pilot participants which led to discharge from the program. The cohort sample 
size was small due to the lack of CGM during pregnancy users enrolled in the healthcare 
maintenance organization. Some primary obstetrical providers prefer to manage the blood 
glucose of their patients without referral to the program, while some patients prefer to be 
managed in clinic weekly and chose to not use the telephone appointment capabilities of the 
registered nurses, however, the specified statistics were not available for analysis in this project. 
The pilot project discussion began with leadership in December 2019. The decision was 
made to start screening patients during the recruitment process in June 2020 when the first CGM 
during pregnancy users were referred to the program. The recruitment process began before the 
pilot implementation since patient are typically referred very early in the pregnancy, and because 





Considerable literature is limited of long term random controlled trials involving CGM 
use during pregnancy and are on-going. For this reason, CGM education and training modules 
and the NP-developed insulin titration protocol was created specifically for the pilot. As the on-
going studies progress, new information will be elicited. A major weakness of the studies 
reviewed for the pilot was that none discuss maternal and fetal outcomes as an important theme 
worthy of research. Among the articles, researchers (Polsky & Garcetti, 2017) determined more 
studies are needed to conclude long term benefits and neonatal and maternal outcomes. The link 
of nocturnal hyperglycemia to that of large for gestational age (LGA) neonates was attempted by 
Battolino, et al. (2019) but the study authors failed to specifically correlate the data as such, 
concluding with a need for more studies. Limiting the data by not conducting follow up studies 
of this important dataset means clinicians will continue to work to decrease daytime 
hyperglycemia without knowing if basal insulin should be titrated to decrease nocturnal 
hyperglycemia, potentially preventing LGA neonates who require intensive care following birth. 
Conclusions 
The findings from the pilot project, while supported by the literature, indicate that the 
interpretation of continuous blood glucose reports is an essential function of registered nurses 
who provide care for pregnant women who use CGM with diabetes. However, to perform this 
essential function during the pilot, registered nurses were provided a protocol to follow and 
CGM education and training to interpret the critical CGM report data. A lack of CGM education 
and training was a barrier that subsequently delayed care and had a negative impact on the 
patient’s blood glucose control during pregnancy. As a result of the pilot program, pregnant 





decreased episodic hypoglycemia, zero episodes of nocturnal hypoglycemia unawareness, 
improved HgbA1c, and vaginal delivery of normal weight infants who did not require neonatal 
intensive care unit stay. 
The following recommendations are made for providing evidence-based care to pregnant 
women who use CGM device technology during pregnancy. Nurse practitioners possess the 
skills, education, training, and leadership experience to train registered nurses on CGM report 
interpretation. CGM education and training should be made widely available by nurse 
practitioners to all registered nurses who provide care for patients who use CGM devices. 
Registered nurses should be allowed to perform independent and dependent functions when 
using a nurse practitioner-developed protocol to provide care for pregnant women with diabetes 
who use continuous glucose monitoring during pregnancy. Evidence supports educating and 
training registered nurses on continuous glucose management device technology to improve 
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Review of Evidence Grid 
Key:   Johns Hopkins Nursing Evidence-Based Practice Research Evidence Appraisal Tool LOE: level of evidence (LoBiondo-Wood & Haber) 







Synthesis  of Findings 
Evidence That Answers the EBP Question 
Level I 
■ Experimental study 
■ Randomized controlled trial (RCT) 
■ Systematic review of RCTs with or without meta-
analysis 
■ Explanatory mixed method design that includes 
only a Level I quantitative study 
4 A: High 
Quality 
1. CGM training should be made 
widely available to clinicians such 
as nurses and NPs, Formal 
certification would add to more 
barriers and isn’t necessary. 
Clinician training should be 
expanded. 
2. Dexcom G6 CGM is a reliable 
tool during pregnancy. Accuracy 
of CGM results associated with 
placement on upper arm. CGM 
may be beneficial to women with 
other types of DM. Limitation is 
small sample size (32 pregnant 
women 18-34 yrs old; 15 T1D 
using MDI; 5 T1D using CSII; 3 
T2D, 9 GDM), (Castorino, et. al., 
2020). 
3. TIR streamlines data 
interpretation and provides more 
information than A1c alone and 
facilitates safe and effective 
therapeutic decision-making 
within glycemic parameters. TIR 
should be increased during 
pregnancy as quickly as possible. 
Clinician inexperience in data 
interpretation plays a role in the 
underutilization of CGM use 
during pregnancy. (Battelino, et. 
al., 2019). 
4. This study analyzed data of 132 
women on the impact of CGM on 
maternal, fetal, and neonatal 
outcomes by attempting to explain 
the trimester-specific timeframe 
contributing to LGA by 
identifying BG variability. There 
was no significant difference in 
mean A1c levels among mothers 
w/ LGA infants compared to those 
w/o LGA infants; DM pregnancies 
were clinically well controlled. 






■   Quasi-experimental studies 
■    Systematic review of a combination of RCTs and 
quasi-experimental studies, or quasi-
experimental studies only, with or without meta-
analysis 
■ Explanatory mixed method design that includes 
only a Level II quantitative study 
3 A: High 
Quality 
1. Lack of training for healthcare 
providers. CGM is safe in 
pregnancy when used in 
conjunction with RGM. CGM is 
beneficial as adjunctive glucose 
management tool in pregnancy 
(Polsk & Garcetti, 2017). 
2. CGM can effectively be used in 
patients using MDI or CSII. TIR 
has been standardized as 70-180 
mg/dl and is established as a 
specific target range for 
pregnancy. CGM use is corelated 
with a reduction of DM 
complications. (Gabbay, et. al, 
2020). 
3. 82 women completed the study 
which demonstrated the 
physiological importance of tight 
glycemic control in minimizing 
perinatal complications. CGM in 
pregnancy identified significant 
daily glucose variability otherwise 
missed by standard care (SMBG).  
(Mazze, et. al., 2012). 
Level III 
■  Nonexperimental study 
■  Systematic review of a combination of RCTs, 
quasi-experimental and nonexperimental 
studies, or nonexperimental studies only, with or 
without meta- analysis 
■  Qualitative study or meta- synthesis 
■  Exploratory, convergent, or multiphasic mixed-
methods studies 
■ Explanatory mixed method design that includes 
only a level III Quantitative study 
3  1.  Observational cohort study. 
CGM’s role in improving TIR, 
improved fetal outcomes. LGA is 
semester specific. Lower A1c in 
first trimester, with higher BG 
variability and less TIR associated 
with LGA (Kristensen, et. al., 
2019). 
2. Reduced in-person clinic visits d/t 
CGM and RGM lowers costs. 
HbA1c is naturally lower by 0.5% 
during pregnancy d/t short 
lifespan of RBC, increased 
erythropoiesis. (Stewart, et. al., 
2019). 
3. Explains the patho/physiology of 
GDM, insulin resistance, glucose 
intolerance, and metabolic 
dysfunction as contributing factors 
to variable blood glucose during 
pregnancy. Cites ACOG and other 
governing body guidelines and 
recommendations, give extensive 
background on CGM use and 

















Synthesis  of Findings 
Evidence That Answers the EBP 
Question 
Level IV 
■   Opinions of respected authorities and/or 
reports of nationally recognized expert 
committees or consensus panels based on 
scientific evidence 
2 B: Good Quality 
A: Good Quality 
1. CGM was more helpful in 
T1D. and demonstrated 
postprandial hyperglycemia 
and nocturnal hypoglycemia 
that was either not evident or 
underestimated by SBMG. 
CGM improves clinical 
decision-making; most 
common change was 
decreasing long-acting or 
intermediate-acting insulin d/t 
previously undetected 
nocturnal hypoglycemia. 
(Sung, Taslimi, & Faig, 2012). 
2. CGM training should be 
made widely available to 
clinicians such as nurses 
and NPs, Formal 
certification would add to 
more barriers and isn’t 
necessary. Clinician 
training should be 
expanded. (Fonseca, et. al, 
2016). 
Level V 
■   Evidence obtained from literature or 
integrative reviews, quality improvement, 
program evaluation, financial evaluation, 
or case reports 
■   Opinion of nationally recognized expert(s) 
based on experiential evidence 
   
 
 
Recommendations based on evidence synthesis and selected translation pathway 
Evidence is compelling and strong that registered nurses should be trained on CGM device technology. Specialized certification is not 
necessary and is a barrier to expanding the use of CGM during pregnancy. With training, registered nurses work within their scope to use 
CGM device technology in their work when caring for this population. Recommendation to conduct a pilot study to test implementation of a 
new protocol to be used by registered nurses to titrate insulin dosages for women using CGM as adjunct therapy to multiple daily injections to 
control diabetes during pregnancy. The implementation site is appropriate to test this pilot, is compatible with the cultural values and norms as 
recommended by industry experts, is consistent with practices of the unit and organizational priorities. The implementation pilot is feasible and 
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• Continuity of care 
• Increased patient safety 
• Convenience of TAV 
• 16-hour unit support 
• SMART Goals 
• Numerous supporting evidences in 
literature 
• Less patient compliance 
• Unprecedented project proposal 
• Increased patient census 
OPPORTUNITIES THREATS 
• Reduce clinic visits 
• Interdisciplinary Teamwork 
• Vulnerable population 
• Utilize EBP standards  
• RN resistance 
• Lack of Sponsor support 
• Provider resistance 








Work Breakdown Structure 
 
LEVEL 1 LEVEL 2 LEVEL 3 
1 Postpartum Diabetes 
Management 
1.1 Initiation 1.1.1 Evaluation and Recommendation 
1.1.2 Discuss Project Charter 
1.1.3 Deliverable: Project Charter 
Submission 
1.1.4 Sponsor Charter Review 
1.1.5 Signed/Approved Project Charter 
 1.2 Planning 1.2.1 Preliminary Scope Statement 
1.2.2 Project Team Selection 
1.2.3 Project Plan Kickoff Meeting 
1.2.4 Project Plan Development 
1.2.5 Project Plan Submission 
1.2.6 Milestone: Project Plan Approval 
 1.3 
Execution 
1.3.1 Project Kickoff Meeting 
1.3.2 RN Requirements Verify/Validation 
1.3.3 Policy & Procedure Design 
1.3.4 Deliverable: P&P Submission 
1.3.5 Sponsor P&P Review 
1.3.6 Signed/Approved P&P 
1.3.7 RN P&P Training 
1.3.8 Go Live (Pilot) 
 1.4 Control 1.4.1 Project Management 
1.4.2 Project Status Meeting 
1.4.3 Risk Management 
1.4.4 Update Project Management Plan 
 1.5 Closeout 1.5.1 Procurement Audit 
1.5.2 Lessons Learned Session 
1.5.3 Update Files 
1.5.4 Gain Formal Acceptance 









Estimated Cost Material/Resources 
$77.00 (36)  RN Paid Training: 1 hour 
$0 Pretest (Qualtrics) 
$0 Posttest (Qualtrics) 
$0 Pretest (Qualtrics) 
$0 Posttest (Qualtrics) 











Doctor of Nursing Practice 
Statement of Non-Research Determination (SOD) Form 
 




Last Name: Beamish  First Name: Nicole 
     
CWID Number: 20381945  Semester/Year: Summer 2019 
     
Course Name & 
Number: 
N7005 Population Health Leadership and Teamwork in Project Planning 
     
Chairperson 
Name: 





1. Title of Project 
 
Remote Glucose Monitoring and Continuous Glucose Monitoring Blood Glucose Report Interpretation in 
a   Regional Perinatal Service Center staffed by nurses in a telehealth setting 
 
2. Brief Description of Project 
 










3. AIM Statement: What are you trying to accomplish?  
Complete this statement: 
 
To increase the knowledge of nurses providing care to pregnant women referred using continuous 
glucose monitoring, remote glucose monitoring, and blood glucose report interpretation 
(process/outcome) from 0% (baseline %, rate, #, etc.) to 100% (goal/target %, rate, #, etc.) by 3 months 
(date, 3 - 6-month timeframe) for registered nurses at the implementation unit (population impacted). 
4 Brief Description of Intervention (150 words). 
 
 
 4a. How will this intervention be implemented?  
• Where will you implement the project?  
• Attach a letter from the agency with approval of your project. 
• Who is the focus of the intervention? 
• How will you inform stakeholders/participants about the project and the intervention? 
The purpose of the project is to educate perinatal nurses on continuous glucose monitoring (CGM), remote 
glucose monitoring (RGM), and blood glucose (BG) report interpretation for women with gestational and 
chronic diabetes.  
This is a major nursing practice change that will educate the nurses on CGM, RGM, and BG report 
interpretation using Medtronic CareLink and Dexcom Clarity platforms. For 18+ years, the nursing staff have 
titrated insulin for women during pregnancy using a strict protocol. Nurses do not currently titrate insulin for 
pump users because they do not have insulin pump certification, and most nurses at the service center don't 
know how to interpret the CGM reports.  
The intervention will be the creation of a CGM and RGM report interpretation algorithm that will allow the 
registered nurses to feel confident titrating insulin dosages. The new algorithm will be based on an existing 
algorithm of a 10% or 20% maximum insulin titration that relies upon the patient’s current BMI, hypoglycemic 
history, gestational age, and current insulin dosages. 
A pre-education survey will be given to the registered nurses to measure their confidence, knowledge, and degree 
of education needed to effectively implement the algorithm.  
The project will be implemented at the implementation unit in Northern California. 
The focus of the intervention are the registered nurses. 
The stakeholders and participants will be informed about the project and the intervention by the project leader, 







5. Outcome measurements: How will you know that a change is an improvement?  
• Measurement over time is essential to QI. Measures can be outcome, process, or balancing 
measures. Baseline or benchmark data are needed to show improvement.  
• Align your measure with your problem statement and aim.  
• Try to define your measure as a numerator/denominator. 
o What is the reliability and validity of the measure? Provide any tools that you will use as 
appendices. 
o Describe how you will protect participant confidentiality. 
 
    
           Outcome measurements will be based on the post-education surveys given to the registered 
nurses and compared to the pre-education surveys to determine if an increase in nurse competence and 
knowledge exists within 3 months of implementation, with a goal of 100% of the nurses reporting an 








DNP Statement of Determination  
Evidence-Based Change of Practice Project Checklist* 
The SOD should be completed in NURS 7005 and NURS 791E/P or NURS 749/A/E 
 
Project Title: 
Remote Glucose Monitoring and Continuous Glucose Monitoring Blood Glucose Report Interpretation in 
a   Regional Perinatal Service Center staffed by nurses in a telehealth setting 
 
 
Mark an “X” under “Yes” or “No” for each of the following statements: Yes No 
The aim of the project is to improve the process or delivery of care with established/ accepted 
standards, or to implement evidence-based change. There is no intention of using the data for 
research purposes. 
X  
The specific aim is to improve performance on a specific service or program and is a part of 
usual care. All participants will receive standard of care. 
X  
The project is not designed to follow a research design, e.g., hypothesis testing or group 
comparison, randomization, control groups, prospective comparison groups, cross-sectional, 
case control). The project does not follow a protocol that overrides clinical decision-making. 
X  
The project involves implementation of established and tested quality standards and/or 
systematic monitoring, assessment or evaluation of the organization to ensure that existing 
quality standards are being met. The project does not develop paradigms or untested methods 
or new untested standards. 
X  
The project involves implementation of care practices and interventions that are consensus-
based or evidence-based. The project does not seek to test an intervention that is beyond 
current science and experience. 
X  
The project is conducted by staff where the project will take place and involves staff who are 
working at an agency that has an agreement with USF SONHP. 
X  
The project has no funding from federal agencies or research-focused organizations and is not 
receiving funding for implementation research. 
X  
The agency or clinical practice unit agrees that this is a project that will be implemented to 
improve the process or delivery of care, i.e., not a personal research project that is dependent 
upon the voluntary participation of colleagues, students and/ or patients. 
X  
If there is an intent to, or possibility of publishing your work, you and supervising faculty and the 
agency oversight committee are comfortable with the following statement in your methods 
section: “This project was undertaken as an Evidence-based change of practice project at X 







Answer Key:  
• If the answer to all of these items is “Yes”, the project can be considered an evidence-based activity 
that does not meet the definition of research. IRB review is not required. Keep a copy of this checklist 
in your files.  
• If the answer to any of these questions is “No”, you must submit for IRB approval. 
 
*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human Research Committee, 
Partners Health System, Boston, MA.   
 
To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the criteria 




DNP Statement of Determination  
Evidence-Based Change of Practice Project Checklist Outcome 
The SOD should be completed in NURS 7005 and NURS 791E/P or NURS 749/A/E 
 
Project Title: 
 Remote Glucose Monitoring and Continuous Glucose Monitoring Blood Glucose Report Interpretation 
in a   Regional Perinatal Service Center staffed by nurses in a telehealth setting 
 
 
☑ This project meets the guidelines for an Evidence-based Change in Practice Project as outlined in the 
Project Checklist (attached). Student may proceed with implementation. 
☐ This project involves research with human subjects and must be submitted for IRB approval before 
project activity can commence. 
 
Comments: This project will not require IRB approval because no human subjects are needed to 
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Nicole 
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Chairperson 
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Daily N/A N/A Daily 
Conduct Staff 
Training 
Will Provide Advise Advise Will Receive 
Analyze 
Qualtrics 
Responsible Advise Advise N/A 
Pay Staff for 
Training 
N/A N/A Will Approve N/A 
Implement Pilot Project Manager N/A Advise N/A 
Call Patients to 
collect data 
N/A N/A N/A Responsible 
Call Patients for 
dietary consult 








Qualtrics Pre-Education and Training Survey 
Strongly 
Disagree 
Disagree Undecided Agree Strongly 
Agree 
1 2 3 4 5 
Answer the following questions using the scale above.  
1. I am familiar with the term,” Continuous Glucose Monitoring”.  
2. I have had at least one patient using CGM assigned to the desk I have been 
working on this year.  
3. I feel confident providing care to patients using CGM. 
4. For patients using CGM, I titrate insulin for the patient and route the report to the 
provider afterwards. 
5. For patients using CGM, I collect blood glucose only then route the blood glucose 
report to the provider for a new insulin titration order.  
6. I would participate if offered training on CGM. 
7. If CGM training included blood glucose and CGM report interpretation, I would 






CGM Training Modules 
Appendix J 
Module 1 • Review Medtronic Guardian CGM device and CareLink 
software 
• Review Dexcom G6 CGM device and Clarity software 
o Terminology 
o Blood glucose report selection 
o Blood glucose report interpretation 
Module 2 • CGM documentation 
• CGM Communication and Data Sharing 
Module 3 • New NP-developed insulin titration protocol 
o For patients using multiple daily injections 
Module 4 • Case study 
o Accurately identify pertinent information 







Provider-developed Insulin Titration Protocol 
The table below shows the recommended values for glucose targets. 
 Plasma Glucose Goals 
Fasting 60-90 mg/dL 
Preprandial 60-100 mg/dL 
1-hour Postprandial from beginning of food intake <130 mg/dL 
2 am – 3 am >60 mg/dL 
 
If inadequate control is reflected by two or more elevated fasting (>95 mg/dL) in one week or 
two or more elevated 1-hour postprandial glucose (>140 mg/dL) in one week, despite dietary and 
exercise compliance, the following medication guidelines will apply. 
Assessment 
A. Understanding all adherence to diet, exercise recommendations. 
B. Ongoing knowledge and understanding of pregnancy process complicated by diabetes 
during pregnancy. 
C. Adherence with insulin regimen. 
D. Review of any signs or symptoms of hypo- and hyperglycemia. 
Planning 
A. Log onto CGM device platform. 
B. Review CGM trending and Time in Range reports with patients using CGM technology 
during pregnancy. 







Intervention and Evaluation 
A. Severely elevated fasting blood glucose: CGM report evaluation of fasting blood glucose 
is >110 mg/dL for 2 days, patient will notify the registered nurse. The registered nurse 
will evaluate for obvious etiology. If elevation for 2 or more, refer to medication 
management. 
B. Moderately elevated fasting blood glucose: CGM report evaluation of fasting blood 
glucose is 95-110 mg/dL for 2 days, registered nurse will verify adherence to diet and 
exercise recommendations. If patient has been adhering to diet and exercise 
recommendations, refer to provider for further evaluation or follow medical management. 
If patient has not been adhering to diet and exercise recommendations, nurse will discuss 
methods to improve adherence and develop a plan agreed upon by the patient. 
C. Elevated postprandial glucose: if CGM report evaluation of 1-hour postprandial is >180 
the registered nurse will verify adherence to diet and exercise recommendations. If 
patient has been adhering to diet and exercise recommendations, refer to provider for 
further evaluation or follow medication management. If patient has not been adhering to 
diet and exercise recommendations, the registered nurse will discuss methods to improve 
adherence and develop a plan agreed upon by the patient. 
Medication Management 
A. Adjust insulin dosages based on the following guidelines unless patient can attribute 
abnormal CGM reported values to dietary changes or illness. 






C. Based on the current protocol, registered nurses can increase rapid acting, short or 
intermediate insulin to a maximum of 18 units. If a higher dose is necessary, the primary 
obstetrical or maternal fetal medicine provider must be consulted. 
D. Total insulin dose change should not exceed 20% of the previous insulin dose, unless 
orders for a greater percent change has been obtained and documented in the patient’s 
chart. Any increase should be rounded up to the next even increment. 
E. Prior to an insulin increase of 20%, verify any previous history of nocturnal 
hypoglycemia. If patient has a history of hypoglycemia or nocturnal hypoglycemia, 
increase insulin to a maximum of 10% or consult with the primary obstetrical or maternal 
fetal medicine provider. 
F. Post insulin increase of 20%, the registered nurse will instruct the patient to conduct a 
safety check at 3 am or endure CGM hypoglycemia alarms are set appropriately. 
Note: Adapted from “Patient Care Guidelines: Home Management Insulin Requiring Diabetes 
























Continuous Glucose Monitoring During Pregnancy: Post-Education and 
Training Survey 
 
Start of Block: Default Question Block 
Q1 Since completing the Continuous Glucose Monitoring and Diabetes Management During Pregnancy 
education and training modules, I feel competent with professional documentation in the EHR. 
______ Not at all (1) 
______ Somewhat (2) 
______ Completely competent (3) 
 
Q2 I have cared for patients using Continuous Glucose Monitoring and Diabetes Management During 
Pregnancy before the CGM education and training modules. 
o Not at all  (1)  
o Almost never  (2)  
o Some of the time  (3)  
o Most of the time  (4)  
o All of the time  (5)  
 
Q3 Since completing the CGM education and training modules, my knowledge of Continuous Glucose 
Monitoring and Diabetes Management During Pregnancy has increased. 
o Not at all  (1)  
o A minor amount  (2)  
o A moderate amount  (3)  







Q4 The CGM module education level was appropriate for my learning. 
o Not at all  (1)  
o Somewhat  (2)  
o I Completely agree  (3)  
 
Q5 The CGM module education utilized graphics and provided transcripts that enhanced my learning. 
o Not at all  (1)  
o Somewhat  (2)  
o A moderate amount  (3)  
o I completely agree  (4)  
 
Q6 After completing the CGM modules, I feel competent providing care for patients using multiple daily 
injections and CGM as adjunctive therapy. 
o Extremely competent  (1)  
o Moderately competent  (2)  
o Slightly competent  (3)  
o Neither competent nor incompetent  (4)  
o Slightly incompetent  (5)  
o Moderately incompetent  (6)  








Q7 After completing the CGM education and training modules, I have a clear understanding of the NP-
Developed CGM Insulin Titration Protocol. 
o Not at all  (1)  
o Some understanding  (2)  
o Complete understanding  (3)  
 
 
Q8 After completing the CGM education and training modules, I feel competent providing care to users 
of CGM technology and using the NP-Developed CGM Insulin Titration Protocol. 
o Extremely competent  (1)  
o Moderately competent  (2)  
o Slightly competent  (3)  
o Neither competent nor incompetent  (4)  
o Slightly incompetent  (5)  
o Moderately incompetent  (6)  








Q9 After completing the CGM education and training modules, I feel confident answering my patient's 
questions of CGM technology and use during pregnancy. 
o Extremely confident  (1)  
o Moderately confident  (2)  
o Slightly confident  (3)  
o Neither competent nor incompetent  (4)  
o Slightly incompetent  (5)  
o Moderately incompetent  (6)  
o Extremely incompetent  (7)  
 
Q10 After completing the CGM education and training modules, I will seek CGM Certification to further 
enhance my learning. 
o Not at all likely  (1)  
o Somewhat likely  (2)  
o Moderately likely  (3)  
o Highly likely  (4)  
o Definitely  (5)  
 
End of Block: Default Question Block 
 
Note: CGM During Pregnancy and Diabetes Management Qualtrics Post-Education Survey, 
2020, https://usfca.qualtrics.com/Q/EditSection/Blocks?SurveyID=SV_9GgRuejGUWBKG6V. 







Provider-developed Insulin Titration Protocol 
 Insulin Adjustment 
 Plasma BMI < 29 BMI >/= 29 
Fasting/Pre-breakfast 
Mean BG < 60 Decrease evening or HS 
NPH  by 20% or a 
minimum of 2 units 
Decrease evening or HS 
NPH by 20% or a 
minimum of 2 units 
Mean BG 60-95 No change in NPH No change in NPH 
Mean BG 96-110 Increase evening or HS 
NPH by 10% 
Increase evening of HS 
NPH by 20% 
Mean BG >110 Increase evening of HS 
NPH by 20% 
Increase evening of HS 
NPH by 20% 
1 hour after breakfast 
Mean BG <130 No change No change 
Mean BG 130-160 Increase pre-breakfast 
Regular by 10% or 
increase Rapid-acting 
insulin at breakfast by 
10% 
Increase pre-breakfast 
Regular by 20% or 
Increase Rapid-acting 
insulin at breakfast by 20% 
Mean BG >160 Increase pre-breakfast 
Regular by 20% or 
increase Rapid-acting 
insulin at breakfast by 
20% 
Increase pre-breakfast 
Regular by 20% or 
Increase Rapid-acting 
insulin at breakfast by 20% 
1 hour after lunch    
Mean BG <130 No Change No Change 
Mean BG 130-160 Increase pre-breakfast 
NPH by 10% or Increase 
pre-lunch Regular by 
10% or increase Rapid-
acting insulin at lunch by 
10% 
Increase pre-breakfast 
NPH by 20% or Increase 
pre-lunch Regular by 20% 
or increase Rapid-acting 
insulin at lunch by 20% 
Mean BG >160 Increase pre-breakfast 
NPH by 20% or Increase 
pre-lunch Regular by 
20% or increase Rapid-
acting insulin at lunch by 
20% 
Increase pre-breakfast 
NPH by 20% or Increase 
pre-lunch Regular by 20% 
or increase Rapid-acting 






Mean BG <60 Decrease Pre-breakfast 
NPH by 20% or a 
minimum of 2 units or 
add CHO exchange to 
afternoon snack 
Decrease Pre-breakfast 
NPH by 20% or a 
minimum of 2 units or add 
CHO exchange to 
afternoon snack 
Mean BG 60-110 No change in NPH No change in NPH 
Mean BG 111-130 Increase pre-breakfast 
NPH by 10% or Increase 
Pre-dinner Regular 
insulin by 10% or 
Increase Rapid-acting 
insulin at dinner by 10% 
Increase pre-breakfast 
NPH by 20% or Increase 
Pre-dinner Regular insulin 
by 20% or Increase Rapid-
acting insulin at dinner by 
20% 
Mean BG >130 Increase pre-breakfast 
NPH by 20% or Increase 
Pre-dinner Regular 
insulin by 20% or 
Increase Rapid-acting 
insulin at dinner by 20% 
Increase pre-breakfast 
NPH by 20% or Increase 
Pre-dinner Regular insulin 
by 20% or Increase Rapid-
acting insulin at dinner by 
20% 
1 hour after dinner 
Mean BG <130 No change No change 
Mean BG 130-160 Increase Pre-breakfast 
NPH by 10% or Increase 
Pre-dinner Regular 
insulin by 10% or 
Increase Rapid-acting 
insulin at dinner by 10% 
Increase Pre-breakfast 
NPH by 20% or Increase 
Pre-dinner Regular insulin 
by 20% or Increase Rapid-
acting insulin at dinner by 
20% 
Mean BG >160 Increase Pre-breakfast 
NPH by 20% or Increase 
Pre-dinner Regular 
insulin by 20% or 
Increase Rapid-acting 
insulin at dinner by 20% 
Increase Pre-breakfast 
NPH by 20% or Increase 
Pre-dinner Regular insulin 
by 20% or Increase Rapid-
acting insulin at dinner by 
20% 
 
Note: Adapted from “Patient Care Guidelines: Home Management Insulin Requiring Diabetes 








ADA Recommended Pregnancy Guidelines by Diabetes Type 
 
Variable Gestational Diabetes 
(GDM) 
Type 2 Diabetes 
(DM2) 




Fasting: <95 mg/dL 
One-hour postprandial 
glucose: <140 mg/dL 
Two-hour postprandial 
glucose: <120 mg/dL 




















175 g carbohydrate, 71 
g protein, 28 g fiber 
 
175 g carbohydrate, 
71 g protein, 28 g 
fiber 
 
175 g carbohydrate, 





Insulin is first line 
treatment 
 
Metformin until 12 
weeks GA, then 
glyburide or insulin 
Insulin by multiple 
daily injections or 
insulin pump therapy 
















Risk of Pregnancy 
Loss 
Comparable to that of 
normal pregnancy 
Highest in third 
trimester 
Highest in first 
trimester 
HbA1c <6% <6% or <7% to 
prevent 
hypoglycemia 




Note: Recommended diabetes guidelines for pregnancy by diabetes type. From “Management of 
Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2019” by American Diabetes 








CGM Device Comparison 
 
Note: Comparison of the Dexcom G6 continuous glucose monitoring device and the Medtronic 
Guardian continuous glucose monitoring device. Left panel: Dexcom G6 CGM information. 
From “How it Works”, by Dexcom Continuous Glucose Monitoring, 2020, 
https://www.dexcom.com/g6/how-it-works. Copyright 2020 by Dexcom Continuous Glucose 
Monitoring. Right panel: Medtronic Guardian CGM information. From “Continuous Glucose 
Monitoring”, by Medtronic, 2020, https://www.medtronicdiabetes.com/treatments/continuous-







CGM Software Comparison 
Dexcom Clarity 
 
Note: A sample of the Dexcom Clarity Diabetes Management Software showing blood glucose 
ranges over a 2-day period. Adapted from 2020 Dexcom Clarity Diabetes Management Software 







CGM Software Comparison 
Medtronic CareLink 
 
Note: A sample of the Medtronic Carelink Personal software showing blood glucose data from a 
continuous glucose monitor and glucometer over a 2-week period. Adapted from 2020 Carelink 
Personal Diabetes Software Products, by Medtronic, 2020 








Lewin’s Theory of Change 
 
Note: Lewin’s Theory of Change. Unfreezing: Initial needs assessment identified gap in 
nursing education on CGM technology and delay in care for patients who use CGM during 
pregnancy Change in Practice: Education modules provided to registered nurses on CGM 
technology and the NP-developed protocol for titrating insulin Refreezing: Positive response 
from CGM education modules equipped registered nurses’ utilization of  the NP-developed 
protocol to guide clinical decision-making, no longer delaying care waiting for a new insulin 







CGM Post-Education Survey Data 
 
Note: CGM During Pregnancy and Diabetes Management Post-Education Survey, 2020. 
66.67% of respondents completely agreed the CGM education level was appropriate for 







CGM Post-Education Survey Data 
 
Note: CGM During Pregnancy and Diabetes Management Post-Education Survey, 2020. 
Since completing the CGM education and training modules, 33% or respondents reported 
an increase in knowledge of CGM and diabetes management a significant amount, a 







Hemoglobin A1c Comparison 
 
Note: The Hemoglobin A1c chart shows patients with their starting HbgA1c in blue and the 
final HgbA1c in orange. All but one patient showed a decrease in HgbA1c at the end of the 
pilot or at delivery. 
 
